William D. Hazelton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
William D. Hazelton has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Chung Yin Kong
Division of General Internal Medicine Icahn School of Medicine at Mount Sinai New York New York USA
19 shared publications - Chin Hur
Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA
17 shared publications - Goli Samimi
Division of Cancer Prevention National Cancer Institute Bethesda Maryland USA
14 shared publications - Jason Dennis Wright
Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY
14 shared publications - Tracy M. Layne
Department of Population Health Science and Policy Icahn School of Medicine at Mount Sinai New York New York USA
14 shared publications - Brandy M. Heckman-Stoddard
National Cancer Institute 10 Rockville, MD
13 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Data from Modeled Sojourn Time and Sensitivity for Detecting Preclinical Cancers Retrospectively by a Multicancer Early Detection Test
Background:Blood-based multicancer early detection tests have potential for clinical benefit, but key performance metrics for cancer screening, such as sojourn time and sensitivity of these tests for detecting preclinical disease, are not yet known. Methods:In a retrospective analysis of stored plasma samples in the American Cancer Society Cancer Prevention Study 3 (CPS3), GRAIL’s MCED test was evaluated for detectability prior to cancer diagnosis. Classical state-transition models for cancer screening were modified to characterize the natural history of ctDNA-shedding cancers. The sensitivity estimand for detecting preclinical cancers by the MCED test was proposed in the context of retrospective testing, and a Bayesian likelihood method was developed to estimate preclinical detectable duration and sensitivity. Results:Analysis of CPS3 data showed that for the 12 prespecified cancers that represent two-thirds of cancer deaths in the United States, the test had 64% estimated overall sensitivity across all stages, and 43% sensitivity during an average 1.36-year preclinical detectable window before metastasis. Untestable assumptions on state transition and sensitivity are discussed, along with limitations related to using stored plasma samples. Conclusions:State-transition models were developed for retrospective analysis of plasma samples from the CPS3. Estimates for the length of the preclinical detectable window and the sensitivity at screening support annual MCED screening to intercept late-stage cancers. Impact:Retrospective analysis of plasma samples from the CPS3 supports the potential of GRAIL’s MCED test to detect cancers early in the preclinical state.See related In the Spotlight, p. 1484
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Modeled Sojourn Time and Sensitivity for Detecting Preclinical Cancers Retrospectively by a Multicancer Early Detection Test
Background:Blood-based multicancer early detection tests have potential for clinical benefit, but key performance metrics for cancer screening, such as sojourn time and sensitivity of these tests for detecting preclinical disease, are not yet known. Methods:In a retrospective analysis of stored plasma samples in the American Cancer Society Cancer Prevention Study 3 (CPS3), GRAIL’s MCED test was evaluated for detectability prior to cancer diagnosis. Classical state-transition models for cancer screening were modified to characterize the natural history of ctDNA-shedding cancers. The sensitivity estimand for detecting preclinical cancers by the MCED test was proposed in the context of retrospective testing, and a Bayesian likelihood method was developed to estimate preclinical detectable duration and sensitivity. Results:Analysis of CPS3 data showed that for the 12 prespecified cancers that represent two-thirds of cancer deaths in the United States, the test had 64% estimated overall sensitivity across all stages, and 43% sensitivity during an average 1.36-year preclinical detectable window before metastasis. Untestable assumptions on state transition and sensitivity are discussed, along with limitations related to using stored plasma samples. Conclusions:State-transition models were developed for retrospective analysis of plasma samples from the CPS3. Estimates for the length of the preclinical detectable window and the sensitivity at screening support annual MCED screening to intercept late-stage cancers. Impact:Retrospective analysis of plasma samples from the CPS3 supports the potential of GRAIL’s MCED test to detect cancers early in the preclinical state.See related In the Spotlight, p. 1484
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Modeled Sojourn Time and Sensitivity for Detecting Preclinical Cancers Retrospectively by a Multicancer Early Detection Test
Consistency and robustness of MLEs for the three-state model.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Modeled Sojourn Time and Sensitivity for Detecting Preclinical Cancers Retrospectively by a Multicancer Early Detection Test
Consistency and robustness of MLEs for the three-state model.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Mats and Methods from Modeled Sojourn Time and Sensitivity for Detecting Preclinical Cancers Retrospectively by a Multicancer Early Detection Test
The main file for supplementary Materials and Methods.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Mats and Methods from Modeled Sojourn Time and Sensitivity for Detecting Preclinical Cancers Retrospectively by a Multicancer Early Detection Test
The main file for supplementary Materials and Methods.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Modeled Sojourn Time and Sensitivity for Detecting Preclinical Cancers Retrospectively by a Multicancer Early Detection Test
Consistency and robustness of MLE for the five-state model.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Modeled Sojourn Time and Sensitivity for Detecting Preclinical Cancers Retrospectively by a Multicancer Early Detection Test
Consistency and robustness of MLE for the five-state model.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Modeled Sojourn Time and Sensitivity for Detecting Preclinical Cancers Retrospectively by a Multicancer Early Detection Test
Estimates of test sensitivity and mean sojourn time (MST) by cancer group using less informative priors on test sensitivity.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Modeled Sojourn Time and Sensitivity for Detecting Preclinical Cancers Retrospectively by a Multicancer Early Detection Test
Estimates of test sensitivity and mean sojourn time (MST) by cancer group using less informative priors on test sensitivity.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Modeled Sojourn Time and Sensitivity for Detecting Preclinical Cancers Retrospectively by a Multicancer Early Detection Test
Comparison of observed and model-predicted detection rate for cancers diagnosed in different time intervals.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Modeled Sojourn Time and Sensitivity for Detecting Preclinical Cancers Retrospectively by a Multicancer Early Detection Test
Comparison of observed and model-predicted detection rate for cancers diagnosed in different time intervals.
- Open Access
- 2 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (9) , OF1-OF10
Modeled Sojourn Time and Sensitivity for Detecting Preclinical Cancers Retrospectively by a Multicancer Early Detection Test
Background: Blood-based multicancer early detection tests have potential for clinical benefit, but key performance metrics for cancer screening, such as sojourn time and sensitivity of these tests for detecting preclinical disease, are not yet known. Methods: In a retrospective analysis of stored plasma samples in the American Cancer Society Cancer Prevention Study 3 (CPS3), GRAIL’s MCED test was evaluated for detectability prior to cancer diagnosis. Classical state-transition models for cancer screening were modified to characterize the natural history of ctDNA-shedding cancers. The sensitivity estimand for detecting preclinical cancers by the MCED test was proposed in the context of retrospective testing, and a Bayesian likelihood method was developed to estimate preclinical detectable duration and sensitivity. Results: Analysis of CPS3 data showed that for the 12 prespecified cancers that represent two-thirds of cancer deaths in the United States, the test had 64% estimated overall sensitivity across all stages, and 43% sensitivity during an average 1.36-year preclinical detectable window before metastasis. Untestable assumptions on state transition and sensitivity are discussed, along with limitations related to using stored plasma samples. Conclusions: State-transition models were developed for retrospective analysis of plasma samples from the CPS3. Estimates for the length of the preclinical detectable window and the sensitivity at screening support annual MCED screening to intercept late-stage cancers. Impact: Retrospective analysis of plasma samples from the CPS3 supports the potential of GRAIL’s MCED test to detect cancers early in the preclinical state.
- 2 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (9) , OF1-OF10
Open AccessModeled Sojourn Time and Sensitivity for Detecting Preclinical Cancers Retrospectively by a Multicancer Early Detection Test
Background: Blood-based multicancer early detection tests have potential for clinical benefit, but key performance metrics for cancer screening, such as sojourn time and sensitivity of these tests for detecting preclinical disease, are not yet known. Methods: In a retrospective analysis of stored plasma samples in the American Cancer Society Cancer Prevention Study 3 (CPS3), GRAIL’s MCED test was evaluated for detectability prior to cancer diagnosis. Classical state-transition models for cancer screening were modified to characterize the natural history of ctDNA-shedding cancers. The sensitivity estimand for detecting preclinical cancers by the MCED test was proposed in the context of retrospective testing, and a Bayesian likelihood method was developed to estimate preclinical detectable duration and sensitivity. Results: Analysis of CPS3 data showed that for the 12 prespecified cancers that represent two-thirds of cancer deaths in the United States, the test had 64% estimated overall sensitivity across all stages, and 43% sensitivity during an average 1.36-year preclinical detectable window before metastasis. Untestable assumptions on state transition and sensitivity are discussed, along with limitations related to using stored plasma samples. Conclusions: State-transition models were developed for retrospective analysis of plasma samples from the CPS3. Estimates for the length of the preclinical detectable window and the sensitivity at screening support annual MCED screening to intercept late-stage cancers. Impact: Retrospective analysis of plasma samples from the CPS3 supports the potential of GRAIL’s MCED test to detect cancers early in the preclinical state.
- Open Access
- 20 January 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (1) , e71539
Neoadjuvant Chemotherapy Versus Primary Cytoreductive Surgery for Metastatic Endometrial Cancer
Objective: To evaluate the pattern of use and clinical outcomes associated with neoadjuvant chemotherapy (NACT) compared with primary debulking surgery (PDS) in patients with stage IV endometrial cancer. Methods: We utilized the National Cancer Database to identify individuals diagnosed with stage IV endometrial cancer, and categorized them according to receipt of NACT or PDS. Propensity score weighting using inverse probability of treatment weighting was applied. Survival outcomes were evaluated using both an intention‐to‐treat (ITT) analysis, which included all eligible patients, and a per‐protocol (PP) analysis restricted to those who underwent chemotherapy and surgery. Results: Among 18,205 patients, NACT utilization rose from 30.3% in 2010 to 73.8% in 2021 ( p < 0.0001). In the multivariable analysis, patients diagnosed in more recent years, Black and Hispanic race and ethnicity, Medicaid insurance, serous histology, and greater comorbidities were associated with NACT ( p < 0.05). In the ITT analysis, there was no mortality difference within 4 months after diagnosis between NACT patients and PDS patients (aHR = 1.03; 95% CI: 0.96–1.11); however, after 4 months, patients treated with NACT experienced higher mortality than those undergoing PDS (aHR = 1.58; 95% CI: 1.51–1.64). In the PP analysis, NACT patients had lower mortality compared to PDS patients within 24 months after diagnosis (aHR = 0.93; 95% CI, 0.88–0.99) but a 34% higher mortality after 24 months (aHR = 1.34; 95% CI, 1.23–1.47). Conclusion: Utilization of NACT has expanded among patients with metastatic endometrial cancer. Primary debulking surgery with postoperative chemotherapy is linked to higher early mortality but improved long‐term outcomes relative to treatment strategies beginning with NACT followed by surgery.
- 20 January 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (1) , e71539
Open AccessNeoadjuvant Chemotherapy Versus Primary Cytoreductive Surgery for Metastatic Endometrial Cancer
Objective: To evaluate the pattern of use and clinical outcomes associated with neoadjuvant chemotherapy (NACT) compared with primary debulking surgery (PDS) in patients with stage IV endometrial cancer. Methods: We utilized the National Cancer Database to identify individuals diagnosed with stage IV endometrial cancer, and categorized them according to receipt of NACT or PDS. Propensity score weighting using inverse probability of treatment weighting was applied. Survival outcomes were evaluated using both an intention‐to‐treat (ITT) analysis, which included all eligible patients, and a per‐protocol (PP) analysis restricted to those who underwent chemotherapy and surgery. Results: Among 18,205 patients, NACT utilization rose from 30.3% in 2010 to 73.8% in 2021 ( p < 0.0001). In the multivariable analysis, patients diagnosed in more recent years, Black and Hispanic race and ethnicity, Medicaid insurance, serous histology, and greater comorbidities were associated with NACT ( p < 0.05). In the ITT analysis, there was no mortality difference within 4 months after diagnosis between NACT patients and PDS patients (aHR = 1.03; 95% CI: 0.96–1.11); however, after 4 months, patients treated with NACT experienced higher mortality than those undergoing PDS (aHR = 1.58; 95% CI: 1.51–1.64). In the PP analysis, NACT patients had lower mortality compared to PDS patients within 24 months after diagnosis (aHR = 0.93; 95% CI, 0.88–0.99) but a 34% higher mortality after 24 months (aHR = 1.34; 95% CI, 1.23–1.47). Conclusion: Utilization of NACT has expanded among patients with metastatic endometrial cancer. Primary debulking surgery with postoperative chemotherapy is linked to higher early mortality but improved long‐term outcomes relative to treatment strategies beginning with NACT followed by surgery.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 5 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States
Supplemental Table 5: Objective function inputs.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 5 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States
Supplemental Table 5: Objective function inputs.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 8 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States
Supplemental Table 8: Observed and predicted uterine cancer incidence-based mortality.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 8 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States
Supplemental Table 8: Observed and predicted uterine cancer incidence-based mortality.